
Captain T Cell joins Bayer Co.Lab Berlin to accelerate TCR therapies
Ella Day | June 18, 2025 | News story | Analytical & Laboratory Services, Business Services, Research and Development | Bayer Co.Lab, Bayer Co.Lab Berlin, Captain T Cell, Corporate, T-cell receptor therapy, laboratory services
Captain T Cell, a biotech company developing next-generation T-cell receptor (TCR)-based therapies for solid tumours, has announced its selection for Bayer Co.Lab Berlin, a global life sciences incubator. The partnership will support the company’s efforts to advance both autologous and allogeneic TCR-T cell therapy programmes.
The news follows Captain T Cell’s win of the ‘Biggest Scientific Breakthrough’ award at the Grand Opening of Bayer Co.Lab Berlin.
Based at Bayer’s Pharmaceuticals Division headquarters in Berlin, Germany, Bayer Co.Lab Berlin offers resident companies access to lab and office infrastructure, global expertise, and a wider life sciences network. It forms part of Bayer’s international incubator ecosystem, with locations also in Cambridge, US, Kobe, Japan and Shanghai, China.
Captain T Cell’s lead autologous programme, CTC 127, has shown promising preclinical results and is expected to enter clinical trials in 2027. The company is also advancing a first-in-class allogeneic TCR platform, recently achieving key in vivo proof of concept.
“Our proximity to Bayer’s pharma hub will strengthen our clinical and translational strategy and help us develop TCR programmes with real-world impact,” said Felix Lorenz, CEO of Captain T Cell. “We are excited to grow in this environment and continue pushing the boundaries of solid tumour therapy.”
“Bayer Co.Lab exists to support visionary teams tackling the toughest scientific challenges,” added Ruth Shah, head of Bayer Co.Lab Berlin. “We look forward to supporting Captain T Cell in their mission to transform solid tumour treatment through next-generation cell therapies.”
Ella Day
18/6/25
Related Content

Merck KGaA invests in bioresearch and bioproduction
Merck KGaA has bought US life sciences company Millipore Corporation in a $7.2 billion deal …






